Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets

Page 5 of 5

01. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Upside Potential: 60%

On August 23, Eliana Merle, an analyst at UBS, increased the price target for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a pharmaceutical company. The updated price target has been raised by 6.7%, from $60 to $64, effective August 23, 2023. UBS has retained its “Buy” rating for the stock. This adjustment in the price target indicates Eliana Merle’s belief that Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock has the potential to reach $64 within a specified timeframe. The “Buy” rating signifies UBS’s positive perspective on the company’s performance, suggesting that they consider it a favorable investment opportunity.

You can also take a look at 10 Stocks That Will Change the Future and 15 Worst Performing Healthcare Stocks in 2023.

Page 5 of 5